Samson W Fine1, Kiril Trpkov2, Mahul B Amin3, Ferran Algaba4, Manju Aron5, Dilek E Baydar6, Antonio Lopez Beltran7, Fadi Brimo8, John C Cheville9, Maurizio Colecchia10, Eva Comperat11, Tony Costello12, Isabela Werneck da Cunha13, Warick Delprado14, Angelo M DeMarzo15, Giovanna A Giannico16, Jennifer B Gordetsky16, Charles C Guo17, Donna E Hansel18, Michelle S Hirsch19, Jiaoti Huang20, Peter A Humphrey21, Rafael E Jimenez9, Francesca Khani22, Max X Kong23, Oleksandr N Kryvenko24, L Priya Kunju25, Priti Lal26, Mathieu Latour27, Tamara Lotan15, Fiona Maclean14, Cristina Magi-Galluzzi28, Rohit Mehra25, Santosh Menon29, Hiroshi Miyamoto30, Rodolfo Montironi31, George J Netto28, Jane K Nguyen32, Adeboye O Osunkoya33, Anil Parwani34, Christian P Pavlovich35, Brian D Robinson22, Mark A Rubin36, Rajal B Shah37, Jeffrey S So38, Hiroyuki Takahashi39, Fabio Tavora40, Maria S Tretiakova41, Lawrence True41, Sara E Wobker42, Ximing J Yang43, Ming Zhou44, Debra L Zynger34, Jonathan I Epstein45. 1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: fines@mskcc.org. 2. Department of Pathology and Lab Medicine, University of Calgary and Alberta Precision Labs, Calgary, AB, Canada. 3. Department of Pathology and Laboratory Medicine and Urology, University of Tennessee Health Science, Memphis, TN. 4. Department of Pathology, Fundacio Puigvert, Barcelona, Spain. 5. Department of Pathology, University of Southern California, Los Angeles, CA. 6. Department of Pathology, Faculty of Medicine, Koç University, İstanbul, Turkey. 7. Department of Pathology, Champalimaud Centre for the Unknown, Lisbon, Portugal. 8. Department of Pathology, McGill University Health Center, Montréal, QC, Canada. 9. Department of Pathology, Mayo Clinic, Rochester, MN. 10. Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 11. Department of Pathology, Hôpital Tenon, Sorbonne University, Paris, France. 12. Department of Urology, Royal Melbourne Hospital, Melbourne, Australia. 13. Pathology Department, Rede D'OR-Sao Luiz; Sao Paulo, SP, Brazil. 14. Douglass Hanly Moir Pathology, Sydney, Australia. 15. Departments of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD. 16. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN. 17. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. 18. Department of Pathology, Oregon Health and Science University Portland OR, USA. 19. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 20. Department of Pathology, Duke University School of Medicine, Durham, NC. 21. Department of Pathology, Yale School of Medicine, New Haven, CT. 22. Department of Pathology and Laboratory Medicine and Urology, Weill Cornell Medicine, New York, NY. 23. Department of Pathology, Kaiser Permanente Sacramento Medical Center, CA. 24. Departments of Pathology and Laboratory Medicine and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL. 25. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI. 26. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 27. Department of Pathology, CHUM, Université de Montréal, Montréal, QC, Canada. 28. Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL. 29. Department of Surgical Pathology, Tata Memorial Hospital, Parel, Mumbai, India. 30. Departments of Pathology and Laboratory Medicine and Urology, University of Rochester Medical Center, Rochester, NY. 31. Section of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy. 32. Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH. 33. Department of Pathology, Emory University School of Medicine, Atlanta, GA. 34. Department of Pathology, Ohio State University, Columbus, OH. 35. Departments of Urology and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD. 36. Department for BioMedical Research, University of Bern, Bern, Switzerland. 37. Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX. 38. Institute of Pathology, St Luke's Medical Center, Quezon City and Global City, Philippines. 39. Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. 40. Argos Laboratory, Federal University of Ceara, Fortaleza, Brazil. 41. Department of Pathology, University of Washington School of Medicine, Seattle, WA. 42. Departments of Pathology and Laboratory Medicine and Urology, University of North Carolina, Chapel Hill, NC. 43. Department of Pathology, Northwestern University, Chicago, IL. 44. Department of Pathology, Tufts Medical Center, Boston, MA. 45. Departments of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD; Departments of Urology and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD.
Abstract
PURPOSE: To survey urologic clinicians regarding interpretation of and practice patterns in relation to emerging aspects of prostate cancer grading, including quantification of high-grade disease, cribriform/intraductal carcinoma, and impact of magnetic resonance imaging-targeted needle biopsy. MATERIALS AND METHODS: The Genitourinary Pathology Society distributed a survey to urology and urologic oncology-focused societies and hospital departments. Eight hundred and thirty four responses were collected and analyzed using descriptive statistics. RESULTS: Eighty percent of survey participants use quantity of Gleason pattern 4 on needle biopsy for clinical decisions, less frequently with higher Grade Groups. Fifty percent interpret "tertiary" grade as a minor/<5% component. Seventy percent of respondents would prefer per core grading as well as a global/overall score per set of biopsies, but 70% would consider highest Gleason score in any single core as the grade for management. Seventy five percent utilize Grade Group terminology in patient discussions. For 45%, cribriform pattern would affect management, while for 70% the presence of intraductal carcinoma would preclude active surveillance. CONCLUSION: This survey of practice patterns in relationship to prostate cancer grading highlights similarities and differences between contemporary pathology reporting and its clinical application. As utilization of Gleason pattern 4 quantification, minor tertiary pattern, cribriform/intraductal carcinoma, and the incorporation of magnetic resonance imaging-based strategies evolve, these findings may serve as a basis for more nuanced communication and guide research efforts involving pathologists and clinicians.
PURPOSE: To survey urologic clinicians regarding interpretation of and practice patterns in relation to emerging aspects of prostate cancer grading, including quantification of high-grade disease, cribriform/intraductal carcinoma, and impact of magnetic resonance imaging-targeted needle biopsy. MATERIALS AND METHODS: The Genitourinary Pathology Society distributed a survey to urology and urologic oncology-focused societies and hospital departments. Eight hundred and thirty four responses were collected and analyzed using descriptive statistics. RESULTS: Eighty percent of survey participants use quantity of Gleason pattern 4 on needle biopsy for clinical decisions, less frequently with higher Grade Groups. Fifty percent interpret "tertiary" grade as a minor/<5% component. Seventy percent of respondents would prefer per core grading as well as a global/overall score per set of biopsies, but 70% would consider highest Gleason score in any single core as the grade for management. Seventy five percent utilize Grade Group terminology in patient discussions. For 45%, cribriform pattern would affect management, while for 70% the presence of intraductal carcinoma would preclude active surveillance. CONCLUSION: This survey of practice patterns in relationship to prostate cancer grading highlights similarities and differences between contemporary pathology reporting and its clinical application. As utilization of Gleason pattern 4 quantification, minor tertiary pattern, cribriform/intraductal carcinoma, and the incorporation of magnetic resonance imaging-based strategies evolve, these findings may serve as a basis for more nuanced communication and guide research efforts involving pathologists and clinicians.
Authors: Melvin L K Chua; Winnie Lo; Melania Pintilie; Jure Murgic; Emilie Lalonde; Vinayak Bhandari; Osman Mahamud; Anuradha Gopalan; Charlotte F Kweldam; Geert J L H van Leenders; Esther I Verhoef; Agnes Marije Hoogland; Julie Livingstone; Alejandro Berlin; Alan Dal Pra; Alice Meng; Junyan Zhang; Michèle Orain; Valérie Picard; Hélène Hovington; Alain Bergeron; Louis Lacombe; Yves Fradet; Bernard Têtu; Victor E Reuter; Neil Fleshner; Michael Fraser; Paul C Boutros; Theodorus H van der Kwast; Robert G Bristow Journal: Eur Urol Date: 2017-05-13 Impact factor: 20.096
Authors: Aurélien Descazeaud; Mark A Rubin; Yves Allory; Martin Burchardt; Laurent Salomon; Dominique Chopin; Claude Abbou; Alexandre de la Taille Journal: Eur Urol Date: 2005-08-09 Impact factor: 20.096
Authors: James L Mohler; Emmanuel S Antonarakis; Andrew J Armstrong; Anthony V D'Amico; Brian J Davis; Tanya Dorff; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Michael Hurwitz; Joseph E Ippolito; Christopher J Kane; Michael R Kuettel; Joshua M Lang; Jesse McKenney; George Netto; David F Penson; Elizabeth R Plimack; Julio M Pow-Sang; Thomas J Pugh; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ahmad Shabsigh; Eric J Small; Daniel E Spratt; Sandy Srinivas; Jonathan Tward; Dorothy A Shead; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2019-05-01 Impact factor: 11.908
Authors: Jennifer B Gordetsky; Luciana Schultz; Kristin K Porter; Jeffrey W Nix; John V Thomas; Maria Del Carmen Rodriguez Pena; Soroush Rais-Bahrami Journal: Hum Pathol Date: 2018-03-16 Impact factor: 3.466
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Fang-Ming Deng; Nicholas M Donin; Ruth Pe Benito; Jonathan Melamed; Julien Le Nobin; Ming Zhou; Sisi Ma; Jinhua Wang; Herbert Lepor Journal: Eur Urol Date: 2015-10-30 Impact factor: 20.096
Authors: Amanda B Hesterberg; Brenda L Rios; Elysa M Wolf; Colby Tubbs; Hong Yuen Wong; Kerry R Schaffer; Tamara L Lotan; Giovanna A Giannico; Jennifer B Gordetsky; Paula J Hurley Journal: J Pathol Clin Res Date: 2021-02-18